March 29, 2024
Volume XIV, Number 89
Home
Legal Analysis. Expertly Written. Quickly Found.
FDA Advertising and Promotion Enforcement Activities in March 2014 - U.S. Food and Drug Administration
Thursday, May 8, 2014

The Office of Compliance (OC) in the FDA’s Center for Devices and Radiological Health issued a warning letter to NeoMedix Corporation regarding the Trabectome High Frequency Generator /LP (Trabectome) on February 26, 2014.

The warning letter included allegations that Neomedix’s website made claims about Trabectome that represented a “major change or modification” of the device’s intended use, including claims for minimally invasive surgical treatment and management of glaucoma.  Because of the website’s claims, OC alleged that the device was adulterated and misbranded.

Additional information on this warning letter, and other enforcement letters related to the advertising and promotion of drugs and biologics, can be found in Covington & Burling LLP’s e-alert for the month of March (available here).

 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins